Helicobacter pylori, gastric cancer and other gastrointestinal malignancies

摘要: In a retrospective study performed in California, U.S.A., ca. 3% of patients with gastric intestinal metaplasia (GIM) developed cancer (GC) within median time period 4.6 years after diagnosis GIM. This observation stresses the importance targeted surveillance even regions low GC prevalence. Patients alcoholic liver disease as well survivors colorectal and lobular breast were found to be at increased risk secondary GC. A population-based Chinese confirmed "serologic biopsy" useful screening tool for stratifying individual developing Concerning therapy, post hoc analysis MAGIC trial reported that regression lymph node metastases, but not tumor itself, predicts overall survival. Furthermore, high microsatellite instable tumors, perioperative chemotherapy leads an mortality. Two studies eradication therapy is worthwhile initial treatment mucosa-associated lymphoid tissue (MALT) lymphoma irrespective H. pylori infection status stage. An second primary malignancy including was observed these treated immuno/chemotherapy solely treatment. With respect gastrointestinal malignancies other than GC, discrepant data have been published regarding association pancreatic whereas no has esophageal squamous cell carcinoma. The majority still support colon neoplasms.